Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie Gourley

Showing results (111-120 of 145) with videos related to

Pageof 15
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the scienceRachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 TrialPaul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2025
Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinomaRobert L Hollis, Michael Churchman, Graeme R Grimes, et al.
Gynecologic Oncology|August 20, 2021
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trialSusana N Banerjee, Monica Tang, Rachel L O'Connell, et al.
The Lancet. Oncology|April 16, 2021
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trialMichael Friedlander, Kathleen N Moore, Nicoletta Colombo, et al.
Genome Medicine|December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparibAlan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient StratificationRobert L Hollis, Alison M Meynert, Caroline O Michie, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 14, 2020
Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of careCharles H Norell, John Butler, Rhonda Farrell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Pageof 15

Showing results (111-120 of 145) with videos related to

Sort By:
Pageof 15
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the scienceRachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 TrialPaul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2025
Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinomaRobert L Hollis, Michael Churchman, Graeme R Grimes, et al.
Gynecologic Oncology|August 20, 2021
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trialSusana N Banerjee, Monica Tang, Rachel L O'Connell, et al.
The Lancet. Oncology|April 16, 2021
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trialMichael Friedlander, Kathleen N Moore, Nicoletta Colombo, et al.
Genome Medicine|December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparibAlan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient StratificationRobert L Hollis, Alison M Meynert, Caroline O Michie, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 14, 2020
Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of careCharles H Norell, John Butler, Rhonda Farrell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Pageof 15